The CEO letter points to the "future" of sc's as well as positioning NBS to capture a share of the market in severasl medically needed areas. I never questioned the ability of NBS to meet their goals. However, I do agree w/you that a company going from $3.50 to .30 has tainted the credibility of NBS to convince investors to buy into the company.
I know several people who lost a considerable amt of money as a result of the drop. I hold a position in NBS well below the current price. A breakout is emminent according to one poster, but never explains the statement. As I said bedore, I'm on hold until I read "difinitive results" inpiring me to buy more. The company has one major problem-credibility.